SCHEMBL20131060

SCHEMBL20131060

Cc1cc(NC(=O)c2c(Cl)ccc(S(N)(=O)=O)c2Cl)ccc1F

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.48
▸ CA2 P00918 9/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CA1 P00915 7/20 0.44
▸ PTGES2 Q9H7Z7 1/20 0.44
▸ CA9 Q16790 4/20 0.44
▸ CA12 O43570 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ STAT3 P40763 1/20 0.42
▸ IDH1 O75874 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20131064 0.85 PTGES2 (0.48) MAPTCA2KMT2ACA1PTGES2
SCHEMBL23677178 0.84 CA1 (0.53) MAPTCA2KMT2ACA1PTGES2
SCHEMBL20131057 0.79 CYP1A2 (0.50) CA2KMT2ACA1PTGES2CA9
SCHEMBL17115712 0.78 HTR2B (0.63) MAPTKMT2AALDH1A1LMNAPOLB
SCHEMBL15613254 0.78 MAPT (0.54) MAPTCA2KMT2ACA1CA9
SCHEMBL21623572 0.75 CYP1A2 (0.74) MAPTCA2KMT2ACA1CA9
SCHEMBL20131046 0.75 CYP1A2 (0.51) MAPTCA2KMT2ACA1PTGES2
SCHEMBL21623209 0.75 CYP1A2 (0.54) MAPTCA2KMT2ACA1CA9
SCHEMBL20458987 0.75 CA2 (0.44) MAPTCA2KMT2ACA1PTGES2
SCHEMBL22763568 0.74 CA1 (0.66) MAPTCA2KMT2ACA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10995064-B2 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B JANSSEN SCIENCES IRELAND UC (IE) 2021-05-04 — — US disclosed
US-20180127361-A1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127361-A1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B SULT2A1, HCCS, SULT1A1 MAPT 4375/4885CA2 3623/4885KMT2A 543/4885
US-10995064-B2 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B SULT2A1, HCCS, SULT1A1 MAPT 4375/4885CA2 3623/4885KMT2A 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback